FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:85-92 July 12, 2001 Number 2 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background It is controversial whether prolonged antibiotic treatment is effective for patients in whom symptoms persist after the recommended antibiotic treatment for acute Lyme disease.

Methods We conducted two randomized trials: one in 78 patients who were seropositive for IgG antibodies to Borrelia burgdorferi at the time of enrollment and the other in 51 patients who were seronegative. The patients received either intravenous ceftriaxone, 2 g daily for 30 days, followed by oral doxycycline, 200 mg daily for 60 days, or matching intravenous and oral placebos. Each patient had well-documented, previously treated Lyme disease but had persistent musculoskeletal pain, neurocognitive symptoms, or dysesthesia, often associated with fatigue. The primary outcome measures were improvement on the physical- and mental-health–component summary scales of the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36) — a scale measuring the health-related quality of life — on day 180 of the study.

Results After a planned interim analysis, the data and safety monitoring board recommended that the studies be discontinued because data from the first 107 patients indicated that it was highly unlikely that a significant difference in treatment efficacy between the groups would be observed with the planned full enrollment of 260 patients. Base-line assessments documented severe impairment in the patients' health-related quality of life. In intention-to-treat analyses, there were no significant differences in the outcomes with prolonged antibiotic treatment as compared with placebo among either the seropositive or the seronegative patients.

Conclusions There is considerable impairment of health-related quality of life among patients with persistent symptoms despite previous antibiotic treatment for acute Lyme disease. However, in these two trials, treatment with intravenous and oral antibiotics for 90 days did not improve symptoms more than placebo.

Source Information

From New England Medical Center and Tufts University School of Medicine, Boston (M.S.K., L.T.H., C.H.S., G.M.J., R.P. T., J.M.); Yale–New Haven Hospital, New Haven, Conn. (J.E., D.W.), New York Medical College, Valhalla (D.N., L.L., A.W.); and Quality Metric, Lincoln, R.I. (M.K.).

Because of its potential importance in the treatment of Lyme disease, this article was published at www.nejm.org on June 12, 2001.

Address reprint requests to Dr. Klempner at the Department of Medicine, Boston University School of Medicine, 715 Albany St., Boston, MA 02118, or at klempner{at}bu.edu.

Full Text of this Article

This article has been cited by other articles:

• Fallon, B. A., Keilp, J. G., Corbera, K. M., Petkova, E., Britton, C. B., Dwyer, E., Slavov, I., Cheng, J., Dobkin, J., Nelson, D. R., Sackeim, H. A. (2008). A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 70: 992-1003 [Abstract] [Full Text]  
• Halperin, J. J. (2008). Prolonged Lyme disease treatment: Enough is enough. Neurology 70: 986-987 [Full Text]  
• Mayer, L., Merz, S., Maloney, E. L., Holmes, K. D., Volkman, D. J., Cameron, D. J., Drapkin, M. S., Feder, H. M. Jr., the Ad Hoc International Lyme Disease Group, (2008). An Appraisal of "Chronic Lyme Disease". NEJM 358: 428-431 [Full Text]  
• Cruz, A. R., Moore, M. W., La Vake, C. J., Eggers, C. H., Salazar, J. C., Radolf, J. D. (2008). Phagocytosis of Borrelia burgdorferi, the Lyme Disease Spirochete, Potentiates Innate Immune Activation and Induces Apoptosis in Human Monocytes. Infect. Immun. 76: 56-70 [Abstract] [Full Text]  
• Tonks, A. (2007). Lyme wars. BMJ 335: 910-912 [Full Text]  
• Feder, H. M. Jr., Johnson, B. J.B., O'Connell, S., Shapiro, E. D., Steere, A. C., Wormser, G. P., the Ad Hoc International Lyme Disease Group, (2007). A Critical Appraisal of "Chronic Lyme Disease". NEJM 357: 1422-1430 [Full Text]  
• Halperin, J. J., Shapiro, E. D., Logigian, E., Belman, A. L., Dotevall, L., Wormser, G. P., Krupp, L., Gronseth, G., Bever, C. T. Jr (2007). Practice Parameter: Treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 69: 91-102 [Abstract] [Full Text]  
• Glatz, M., Golestani, M., Kerl, H., Mullegger, R. R. (2006). Clinical Relevance of Different IgG and IgM Serum Antibody Responses to Borrelia burgdorferi After Antibiotic Therapy for Erythema Migrans: Long-term Follow-up Study of 113 Patients.. Arch Dermatol 142: 862-868 [Abstract] [Full Text]  
• Wormser, G. P. (2006). Clinical practice. Early Lyme disease.. NEJM 354: 2794-2801 [Full Text]  
• Cairns, V. (2005). Author's response to comments by Sigal and Hassett, Phillips et al., and Shapiro et al.. Int J Epidemiol 34: 1440-1443 [Full Text]  
• Cairns, V., Godwin, J. (2005). Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol 34: 1340-1345 [Abstract] [Full Text]  
• Sigal, L. H, Hassett, A. L (2005). Commentary: 'What's in a name? That which we call a rose by any other name would smell as sweet.' Shakespeare W. Romeo and Juliet, II, ii(47-48). Int J Epidemiol 34: 1345-1347 [Full Text]  
• Shapiro, E. D, Dattwyler, R., Nadelman, R. B, Wormser, G. P (2005). Response to meta-analysis of Lyme borreliosis symptoms. Int J Epidemiol 34: 1437-1439 [Full Text]  
• (2005). Treatment of Lyme Disease. Obstet Gynecol 106: 1099-1100 [Full Text]  
• Widhe, M., Skogman, B. H., Jarefors, S., Eknefelt, M., Enestrom, G., Nordwall, M., Ekerfelt, C., Croner, S., Bergstrom, S., Forsberg, P., Ernerudh, J. (2005). Up-regulation of Borrelia-specific IL-4- and IFN-{gamma}-secreting cells in cerebrospinal fluid from children with Lyme neuroborreliosis. Int Immunol 17: 1283-1291 [Abstract] [Full Text]  
• Marques, A. R., Hornung, R. L., Dally, L., Philipp, M. T. (2005). Detection of Immune Complexes Is Not Independent of Detection of Antibodies in Lyme Disease Patients and Does Not Confirm Active Infection with Borrelia burgdorferi. CVI 12: 1036-1040 [Abstract] [Full Text]  
• Philipp, M. T., Wormser, G. P., Marques, A. R., Bittker, S., Martin, D. S., Nowakowski, J., Dally, L. G. (2005). A Decline in C6 Antibody Titer Occurs in Successfully Treated Patients with Culture-Confirmed Early Localized or Early Disseminated Lyme Borreliosis. CVI 12: 1069-1074 [Abstract] [Full Text]  
• Aguero-Rosenfeld, M. E., Wang, G., Schwartz, I., Wormser, G. P. (2005). Diagnosis of Lyme Borreliosis. Clin. Microbiol. Rev. 18: 484-509 [Abstract] [Full Text]  
• Hunfeld, K.-P., Ruzic-Sabljic, E., Norris, D. E., Kraiczy, P., Strle, F. (2005). In Vitro Susceptibility Testing of Borrelia burgdorferi Sensu Lato Isolates Cultured from Patients with Erythema Migrans before and after Antimicrobial Chemotherapy. Antimicrob. Agents Chemother. 49: 1294-1301 [Abstract] [Full Text]  
• Dinser, R, Jendro, M C, Schnarr, S, Zeidler, H (2005). Antibiotic treatment of Lyme borreliosis: what is the evidence?. Ann Rheum Dis 64: 519-523 [Abstract] [Full Text]  
• (2005). February 22 Highlight and Commentary: Borrelia burgdorferi, the brain and biologic plausibility. Neurology 64: 585-585 [Full Text]  
• Grab, D. J., Perides, G., Dumler, J. S., Kim, K. J., Park, J., Kim, Y. V., Nikolskaia, O., Choi, K. S., Stins, M. F., Kim, K. S. (2005). Borrelia burgdorferi, Host-Derived Proteases, and the Blood-Brain Barrier. Infect. Immun. 73: 1014-1022 [Abstract] [Full Text]  
• Wormser, G. P., Nowakowski, J., Nadelman, R. B. (2004). Treatment of Early Lyme Disease. ANN INTERN MED 140: 577-578 [Full Text]  
• Steere, A. C. (2004). Duration of Antibiotic Therapy for Lyme Disease. ANN INTERN MED 140: W-7-W-7 [Full Text]  
• Willett, T. A., Meyer, A. L., Brown, E. L., Huber, B. T. (2004). An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc. Natl. Acad. Sci. USA 101: 1303-1308 [Abstract] [Full Text]  
• Philipp, M. T., Marques, A. R., Fawcett, P. T., Dally, L. G., Martin, D. S. (2003). C6 Test as an Indicator of Therapy Outcome for Patients with Localized or Disseminated Lyme Borreliosis. J. Clin. Microbiol. 41: 4955-4960 [Abstract] [Full Text]  
• Steiner, I. (2003). Treating post Lyme disease: Trying to solve one equation with too many unknowns. Neurology 60: 1888-1889 [Full Text]  
• Kaplan, R. F., Trevino, R. P., Johnson, G. M., Levy, L., Dornbush, R., Hu, L. T., Evans, J., Weinstein, A., Schmid, C. H., Klempner, M. S. (2003). Cognitive function in post-treatment Lyme disease Do additional antibiotics help?. Neurology 60: 1916-1922 [Abstract] [Full Text]  
• Krupp, L. B., Hyman, L. G., Grimson, R., Coyle, P. K., Melville, P., Ahnn, S., Dattwyler, R., Chandler, B. (2003). Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial. Neurology 60: 1923-1930 [Abstract] [Full Text]  
• Hayes, E. B., Piesman, J. (2003). How Can We Prevent Lyme Disease?. NEJM 348: 2424-2430 [Full Text]  
• Wormser, G. P., Ramanathan, R., Nowakowski, J., McKenna, D., Holmgren, D., Visintainer, P., Dornbush, R., Singh, B., Nadelman, R. B. (2003). Duration of Antibiotic Therapy for Early Lyme Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. ANN INTERN MED 138: 697-704 [Abstract] [Full Text]  
• Steere, A. C. (2003). Duration of Antibiotic Therapy for Lyme Disease. ANN INTERN MED 138: 761-762 [Full Text]  
• Cavendish, R. (2003). A Lyme Disease Case Study and Individualized Healthcare Plan. The Journal of School Nursing 19: 81-88 [Abstract]  
• (2003). OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02). Evid. Based Nurs. 6: e1-1 [Full Text]  
• Lorber, B. (2002). Update in Infectious Diseases. ANN INTERN MED 137: 974-980 [Full Text]  
• Steere, A. C. (2002). A 58-Year-Old Man With a Diagnosis of Chronic Lyme Disease. JAMA 288: 1002-1010 [Full Text]  
• Smith, R. P., Schoen, R. T., Rahn, D. W., Sikand, V. K., Nowakowski, J., Parenti, D. L., Holman, M. S., Persing, D. H., Steere, A. C. (2002). Clinical Characteristics and Treatment Outcome of Early Lyme Disease in Patients with Microbiologically Confirmed Erythema Migrans. ANN INTERN MED 136: 421-428 [Abstract] [Full Text]  
• Nadelman, R. B., Wormser, G. P. (2002). Recognition and Treatment of Erythema Migrans: Are We Off Target?. ANN INTERN MED 136: 477-479 [Full Text]  
• Sigal, L. H. (2002). Misconceptions about Lyme Disease: Confusions Hiding behind Ill-Chosen Terminology. ANN INTERN MED 136: 413-419 [Full Text]  
• (2002). ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB. Evid. Based Med. 7: 35-35 [Full Text]  
• Donta, S. T., McCaulley, M. E., Bransfield, R., Brand, S., Sherr, V., Wyler, D. J., Weinstein, A., Klempner, M. S. (2001). Treatment of Patients with Persistent Symptoms and a History of Lyme Disease. NEJM 345: 1424-1425 [Full Text]  
• Pontrelli, L., Dattwyler, R., Nachman, S., Levy, P. D., Kirrane, B. M., Hexdall, A. H., Leenders, A.C.A.P., Bellovin, S. M., Nadelman, R. B., Wormser, G. P., Shapiro, E. D. (2001). Single-Dose Doxycycline for the Prevention of Lyme Disease. NEJM 345: 1348-1350 [Full Text]  
• (2001). Persistent Symptoms of Lyme Disease: Not Necessarily Responsive to Antibiotics. JWatch Neurology 2001: 6-6 [Full Text]  
• Halperin, J. J., Wormser, G. P. (2001). Of Fleas and Ticks on Cats and Mice . . .. Arch Neurol 58: 1345-1347 [Full Text]  
• (2001). Antibiotics for Persistent Symptoms Following Lyme Disease. Journal Watch Dermatology 2001: 4-4 [Full Text]  
• Steere, A. C. (2001). Lyme Disease. NEJM 345: 115-125 [Full Text]  
• (2001). Extended Antibiotic Treatment Doesn't Alter Persistent Post-Lyme Symptoms. JWatch Infect. Diseases 2001: 1-1 [Full Text]  
• (2001). Medicating Lyme Disease Before It Starts and After It Ends. JWatch General 2001: 1-1 [Full Text]